0001140361-21-016824.txt : 20210511 0001140361-21-016824.hdr.sgml : 20210511 20210511163038 ACCESSION NUMBER: 0001140361-21-016824 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210511 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210511 DATE AS OF CHANGE: 20210511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000899866 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133648318 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27756 FILM NUMBER: 21911734 BUSINESS ADDRESS: STREET 1: 121 SEAPORT BOULEVARD CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 4752302596 MAIL ADDRESS: STREET 1: 121 SEAPORT BOULEVARD CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: ALEXION PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960111 8-K 1 brhc10024426_8k.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 8-K



Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 11, 2021


 
ALEXION PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)


 
Delaware
000-27756
13-3648318
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
121 Seaport Boulevard, Boston, Massachusetts 02210
(Address of principal executive offices, including zip code)
 
(475) 230-2596
(Registrant’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
Symbol
 
Name of each exchange
on which registered
Common Stock, par value $0.0001 per share
 
ALXN
 
The Nasdaq Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
 

Item 5.07
Submission of Matters to a Vote of Security Holders.

Alexion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), held its special meeting of stockholders on May 11, 2021 (the “special meeting”). A definitive merger proxy statement on Schedule 14A with respect to the special meeting was filed with the Securities and Exchange Commission on April 13, 2021. Descriptions of each of the proposals voted upon at the special meeting are contained in the definitive merger proxy statement. At the close of business on March 30, 2021, the record date of the special meeting, the Company had 220,912,612 shares of common stock issued and outstanding. The holders of a total of 160,738,262 shares of common stock were present at the special meeting, either in person or by proxy, which constituted a quorum for the purpose of the special meeting.

The following is a summary of the voting results with respect to each of the proposals, including the number of votes cast for and against, and the number of abstentions.

1.            A proposal to adopt the Agreement and Plan of Merger (the “Merger Agreement”), dated as of December 12, 2020 by and among the Company, AstraZeneca PLC (“AstraZeneca”), Delta Omega Sub Holdings Inc., Delta Omega Sub Holdings Inc. 1 and Delta Omega Sub Holdings LLC 2 (the “Merger Proposal”).
 
For
 
Against
 
Abstain
160,441,094
 
187,257
 
109,911

2.            A proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to Alexion’s named executive officers that is based on or otherwise relates to the transactions contemplated by the Merger Agreement.
 
For
 
Against
 
Abstain
150,361,845
 
9,447,868
 
928,549

3.            A proposal to approve the adjournment of the Alexion special meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes at the time of the Alexion special meeting to approve the Merger Proposal or to ensure that any supplement or amendment to Alexion’s proxy statement is timely provided to Alexion stockholders.
 
An adjournment was not necessary in light of adoption of the Merger Proposal.
 
Item 8.01
Other Events.

On May 11, 2021, the Company issued a press release (the “Press Release”) announcing the results of the special meeting. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits.

(d)
Exhibits
 
Exhibit No.
 
Description of Exhibit
     
 
Press Release dated May 11, 2021
     
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)


Additional Information and Where to Find It
In connection with AstraZeneca’s proposed acquisition of Alexion (the “proposed transaction”), AstraZeneca filed with the SEC a registration statement on Form F-4 which includes a proxy statement of Alexion and a prospectus of AstraZeneca. The registration statement was declared effective by the SEC on April 12, 2021, and mailing of the definitive joint proxy statement/prospectus to the shareholders of Alexion occurred on or about April 12, 2021. Each of Alexion and AstraZeneca may also file other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the registration statement and the definitive proxy statement/prospectus and other documents containing important information about Alexion, AstraZeneca and the proposed transaction through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Alexion will be available free of charge on Alexion’s website at http://www.alexion.com or by contacting Alexion’s Investor Relations Department by email at InvestorRelations@alexion.com. Copies of the documents filed with the SEC by AstraZeneca will be available free of charge on AstraZeneca’s website at https://www.astrazeneca.com/investor-relations.html or by contacting AstraZeneca’s Investor Relations department by email at global-mediateam@astrazeneca.com.

Participants in the Solicitation
Alexion, AstraZeneca, their respective directors and certain of their executive officers and other employees may be deemed to be participants in the solicitation of proxies from Alexion’s shareholders in connection with the proposed transaction. Information about Alexion’s directors and executive officers is available in Alexion’s proxy statement for its 2020 annual meeting of shareholders, which was filed with the SEC on March 26, 2020, Alexion’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2020, which was filed with the SEC on February 16, 2021, and other documents subsequently filed by Alexion with the SEC. Information about AstraZeneca’s directors and executive officers is available in AstraZeneca’s Form 20-F filed with the SEC on February 16, 2021, and other documents subsequently filed by AstraZeneca with the SEC. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the definitive joint proxy statement/prospectus filed with the SEC on April 12, 2021 and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. Free copies of these documents may be obtained as described in the paragraphs above.

No Offer Or Solicitation
This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.


Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond Alexion’s and AstraZeneca’s control. Statements in this communication regarding Alexion, AstraZeneca and the combined company that are forward-looking, including anticipated benefits of the proposed transaction, the impact of the proposed transaction on Alexion’s and AstraZeneca’s businesses and future financial and operating results, the amount and timing of synergies from the proposed transaction, the terms and scope of the expected financing for the proposed transaction, the aggregate amount of indebtedness of the combined company following the closing of the proposed transaction, are based on management’s estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond Alexion’s and AstraZeneca’s control. These factors include, among other things, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter. Additional information concerning these risks, uncertainties and assumptions can be found in Alexion’s and AstraZeneca’s respective filings with the SEC, including the risk factors discussed in Alexion’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q, in AstraZeneca’s most recent Annual Report on Form 20-F and in each company’s future filings with the SEC. Important risk factors could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to, the risks that: a condition to the closing the proposed acquisition may not be satisfied; a regulatory approval that may be required for the proposed acquisition is delayed, is not obtained or is obtained subject to conditions that are not anticipated; AstraZeneca is unable to achieve the synergies and value creation contemplated by the proposed acquisition; AstraZeneca is unable to promptly and effectively integrate Alexion’s businesses; management’s time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company declines following the proposed acquisition; legal proceedings are instituted against Alexion, AstraZeneca or the combined company; Alexion, AstraZeneca or the combined company is unable to retain key personnel; and the announcement or the consummation of the proposed acquisition has a negative effect on the market price of the capital stock of Alexion or AstraZeneca or on Alexion’s or AstraZeneca’s operating results. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, what impact they will have on the results of operations, financial condition or cash flows of Alexion or AstraZeneca. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the proposed transaction and/or Alexion or AstraZeneca, AstraZeneca’s ability to successfully complete the proposed transaction and/or realize the expected benefits from the proposed transaction. You are cautioned not to rely on Alexion’s and AstraZeneca’s forward-looking statements. These forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither Alexion nor AstraZeneca assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
ALEXION PHARMACEUTICALS, INC.
   
 
By:
 /s/ Doug Barry
   
Name:
 Doug Barry
   
Title:
 Vice President, Corporate Law

Date: May 11, 2021



EX-99.1 2 brhc10024426_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1


Alexion Shareholders Approve Acquisition by AstraZeneca

BOSTON – May 11, 2021 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting of shareholders held today.

Ludwig Hantson, Ph.D., Chief Executive Officer, Alexion, said: “We’re very pleased with today’s affirmative shareholder vote, which brings us one step closer to completing a transaction that will accelerate the combined company’s ability to develop and provide access to life-changing medicines for patients with rare and devastating diseases around the world.”

Subject to receipt of additional regulatory clearances, the acquisition is expected to close in the third quarter of 2021.

About Alexion
 
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. This press release and further information about Alexion can be found at: www.alexion.com.
 
[ALXN-G]

1

Forward-Looking Statement
 
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond Alexion’s and AstraZeneca’s control. Statements in this communication regarding Alexion, AstraZeneca and the combined company that are forward-looking, including anticipated benefits of the proposed transaction, the impact of the proposed transaction on Alexion’s and AstraZeneca’s businesses and future financial and operating results, the amount and timing of synergies from the proposed transaction, the terms and scope of the expected financing for the proposed transaction, the aggregate amount of indebtedness of the combined company following the closing of the proposed transaction, are based on management’s estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond Alexion’s and AstraZeneca’s control. These factors include, among other things, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter. Additional information concerning these risks, uncertainties and assumptions can be found in Alexion’s and AstraZeneca’s respective filings with the SEC, including the risk factors discussed in Alexion’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q, in AstraZeneca’s most recent Annual Report on Form 20-F and in each company’s future filings with the SEC. Important risk factors could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to, the risks that: a condition to the closing the proposed acquisition may not be satisfied; a regulatory approval that may be required for the proposed acquisition is delayed, is not obtained or is obtained subject to conditions that are not anticipated; AstraZeneca is unable to achieve the synergies and value creation contemplated by the proposed acquisition; AstraZeneca is unable to promptly and effectively integrate Alexion’s businesses; management’s time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company declines following the proposed acquisition; legal proceedings are instituted against Alexion, AstraZeneca or the combined company; Alexion, AstraZeneca or the combined company is unable to retain key personnel; and the announcement or the consummation of the proposed acquisition has a negative effect on the market price of the capital stock of Alexion or AstraZeneca or on Alexion’s or AstraZeneca’s operating results. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, what impact they will have on the results of operations, financial condition or cash flows of Alexion or AstraZeneca. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the proposed transaction and/or Alexion or AstraZeneca, AstraZeneca’s ability to successfully complete the proposed transaction and/or realize the expected benefits from the proposed transaction. You are cautioned not to rely on Alexion’s and AstraZeneca’s forward-looking statements. These forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither Alexion nor AstraZeneca assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date.
 
2

Alexion Contacts:
Media
Megan Goulart, 857-338-8634
Executive Director, Corporate Communications

Investors
Chris Stevo, 857-338-9309
Head of Investor Relations


3

EX-101.SCH 3 alxn-20210511.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 alxn-20210511_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 alxn-20210511_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image00001.jpg begin 644 image00001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# 8$!08%! 8&!08'!P8("A *"@D) M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_ MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P 1" D *(# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#ZIHHI&(52 M20 .23VH &8*0"0,G R>M+7SSXVU[Q#X]\17&O\ 2$E0D>?,#U'J M<9P/0'UKN='^,GAJ3PG;:GJUXMM>D;)K- 6D$@ZX7T/4$\5URP52,4UJ^JZK ML81KQ;:>AZ;2,P526( '4D]*\=C^(GB_Q>YC\">&S!:$X_M#4.$'N!T_]"^E M)H_@S_A*;Z:+Q9XYDUJ[@.9].T^X$<<7."&"\XSQT%+ZKR:U7;RW?X?J/VW- M\"N=[K/CWPOH\ACOM:M!./\ EC$WFR?]\IDU0A\=3ZC@Z%X7UR]0])98EMHS M[AI",C\*V?#_ (1T#P_&JZ/I-I;$?QK&"Y_X$>?UK1U34['2;;[1JEY;V=ON M">9/($7)Z#)[U%Z>T(M^O^2_S*]_>3L84=[XON/NZ1I-FIZ>?>-(1]0J8_6I MUB\5L/FNM%0^@@E;_P!F%'_"<>%?^ACT?_P,C_QI\/C/PS/,D4'B#29)9&"H MBW:$L3T &>M#C/\ D_ +Q_F$\KQ0/^7K1F_[=Y!_[.:>LGB6/_66^D3#_8ED M0G\U-6I?$&D0ZHNFS:I91Z@Q %LTRB0D],+G-:50VUNBDET9FV^HSI'*^JV@ MLD0 F02B1#SCJ.1^(J>WU2QN9A%;7<$TA&[;$X? ]3CI5:R\0:-J-S-:V6J6 M-U/$"98HIU=D X.0#Q61\/[?0+6UU(>';JPN%DNGFE-K*L@7<3M!QTP.WUJ9 M1E?8UA[)P;D_>Z?UY'645SS^-O"Z.R/XBTA64X(-Y'D'\Z3_ (3CPK_T,>C_ M /@9'_C5>RG_ "LRYX]SHJ*SM-US2M4MYI]-U*SNX(?];)!,KJG&>2#QQ1I& MN:7K*R-I&HV=\(\!S;S+)MSTS@\5+C);H?,C1HILCK'&SR,%1069B< =ZI: M3K&FZS"\NDW]K>Q(VUGMY1( ?0D4K.UPNMB_1112&%>*_M">/_[)T]O#FDS8 MO[I,W4BGF&(_P^Q;^7UKUK7Y[^VT>ZETBT%Y?A#Y$)<(&;MDGL.M>5?#GX5. M][=:]\0(5O-9GG,BPNX=$_VFQP3Z#H !79A/90?M:O39=V85N>2Y(=>IP?@& MR\<:_P"'H-'\+0C0]#ZSWI!1IV/WF+_>;TPO '&:?KW@I/A7XCT36;^)-=T6 M1O+NC-"#LD/4@<_49]"*^G(T6- D:A448"J, "L[Q)HMIXBT2[TO48]]M<(5 M/JI[,/<'FMEF#<]K1>Z6_P!_G[*K") HFF6PW"1\$Q^? M;^7(C(V,XSQR.*P]"O/B?H^C66G0^%=,DCM85A5VO!E@HQD_-6K8:W\2I+ZW M2]\+:9%:M(HED6\!*IGD@;NPK:NY2OR2M_V_^AG3LK+P4(YPWJO\NHKQ>/X@^*M>@M_ HN[.'4))S:3:H)A^\0<8##C M)P>1R>!U->K?$^S\8^()(]#\.P+8Z5,0MWJ+S*&*GJJJ#NQZ]STZ5!J'P;\/ MR^#HM'LT,%]#^\CU#'[PR^K>H/IV[4L/5ITZ:59W[=;>?_ '5A*4FX*W?S_K MN=#X0\&Z;X,\,S66G)NF:)FGN6'SS-@\GV]!VKS+]F;_ ) ?BO\ ZZK_ .@M M7>?#Q?&%OI-SI/BZS61X8V2WOTF5O.7H PSG/OCZ\UB_ [P=K7A?2]?@UNV2 MWDNY%:+$JOD;6'8G'45/-:G54Y7;:Z[ZCM>4'%66IQ7[/?A;1/$$/B"36],M MKYX;A%C,R[MH.[.*]:N?AMX-%O*1XGZ!87 M<=W*')ENE&,9QC#>]=;+K?Q2>)T_X1+2AN4C/VP';CQ-X1NF76;&X\MK1 MC^[NHMH)0CU_SP:](^#O@G7O#N@^)XM:MHX;C4!^Y195;)V,.QP.36K\!O"N MK^$_#=[::Y;K!/)<^8JK(KY7:!U!]JUK8F,75<6G=KYZ:DPI-\B:[FEX:\;V M/C#PKJ9B4VNIV]O(EW92?(]VM.J-4I^UCS+:^IZ=1117G'4%%%% !1110 4444 %%%% !11 =10 4444 %%%% !1110 4444 %%%% !1110!__]D! end XML 7 brhc10024426_8k_htm.xml IDEA: XBRL DOCUMENT 0000899866 2021-05-11 2021-05-11 false DE MA 0000899866 8-K 2021-05-11 ALEXION PHARMACEUTICALS, INC. 000-27756 13-3648318 121 Seaport Boulevard Boston 02210 475 230-2596 true false false false Common Stock, par value $0.0001 per share ALXN NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information
May 11, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 11, 2021
Entity Registrant Name ALEXION PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 000-27756
Entity Tax Identification Number 13-3648318
Entity Address, Address Line One 121 Seaport Boulevard
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02210
City Area Code 475
Local Phone Number 230-2596
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000899866
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ALXN
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://alexion.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10024426_8k.htm alxn-20210511.xsd alxn-20210511_lab.xml alxn-20210511_pre.xml brhc10024426_ex99-1.htm http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10024426_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10024426_8k.htm" ] }, "labelLink": { "local": [ "alxn-20210511_lab.xml" ] }, "presentationLink": { "local": [ "alxn-20210511_pre.xml" ] }, "schema": { "local": [ "alxn-20210511.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alxn", "nsuri": "http://alexion.com/20210511", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10024426_8k.htm", "contextRef": "c20210511to20210511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://alexion.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10024426_8k.htm", "contextRef": "c20210511to20210511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alexion.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001140361-21-016824-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-21-016824-xbrl.zip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end